Replies to post #84770 on Biotech Values

[mcbio]

Re: ACHN financing

Are you assuming a "lucrative" partner will come to the rescue at that point? It won't leave them much negotiating room, if so.

I'm assuming that if the Phase 1b results for ACH-1625 are positive, and ACHN does have enough cash to see itself to and beyond those results, then the stock will be much higher upon the announcement of those results, regardless of whether or not they are able to subsequently land any partner. And yes, I do think they'll still be able to land a lucrative partner if the results merit that given the size of the HCV market.

Is there a possibility of them doing a PIPE before then?

Aside from the existing cash, ACHN has entered into a $15 million standby equity agreement to raise additional cash when needed. Please see: #msg-39309704